Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-115 Alone or with Azacitidine/Cytarabine in R/R AML and MDS
NCT04275518Phase 1Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Jul 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of alrizomadlin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Ascentage Pharma. Primary endpoint: Dose Limiting Toxicities. Started Jul 2020; status: recruiting.
02
Drugs
alrizomadlin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04275518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275518.